Source:http://linkedlifedata.com/resource/pubmed/id/16242844
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2005-12-27
|
| pubmed:abstractText |
The control of canine leishmaniasis largely depends on the success of treatment. Drugs currently available to treat this disease are toxic and partially effective. The curative effect of marbofloxacin, a third-generation fluoroquinolone developed for veterinarian individual treatment, was evaluated in vitro in the presence of Leishmania infantum promastigotes and dog-monocyte-derived macrophages; meglumine antimoniate and sodium stibogluconate were used as comparative treatments. We observed that the killing of Leishmania promastigotes and intracellular amastigotes by marbofloxacin was dose-dependent. We demonstrated that successful treatment of canine infected macrophages for 48 h was possible with 500 microg/ml of marbofloxacin. Leishmanicidal activity acted through a TNF-alpha and nitric oxide pathway and correlated with the generation of nitric oxide (NO(2)) production by monocytes derived macrophages from infected (23+/-5 microM) or healthy (21+/-6 microM) dogs, in comparison with NO(2) concentration in infected/non-treated macrophages (< 3 microM, P<0.01). This significant induced parasiticidal effect correlated with extensive elimination of amastigotes by macrophages derived from infected (11+/-5) and healthy dogs (6+/-2), when compared to infected/non-treated macrophages (530+/-105 and 472+/-86 amastigotes, respectively, P< 0.01). Marbofloxacin was shown to be non-toxic at 500 microg/ml in vitro and no cell apoptosis was observed. The molecule was able to induce a parasitic process after significant elimination of amastigotes in leishmania-infected dog macrophages. We propose that marbofloxacin, compared to standard chemotherapeutic agents (meglumine antimoniate and sodium stibogluconate), could be an effective and pragmatic oral route alternative to treat canine leishmaniasis.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimony Sodium Gluconate,
http://linkedlifedata.com/resource/pubmed/chemical/Antiprotozoal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Fluoroquinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Meglumine,
http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Quinolones,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/marbofloxacin,
http://linkedlifedata.com/resource/pubmed/chemical/meglumine antimoniate
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Jan
|
| pubmed:issn |
0304-4017
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:day |
30
|
| pubmed:volume |
135
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
137-46
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16242844-Animals,
pubmed-meshheading:16242844-Antimony Sodium Gluconate,
pubmed-meshheading:16242844-Antiprotozoal Agents,
pubmed-meshheading:16242844-Dog Diseases,
pubmed-meshheading:16242844-Dogs,
pubmed-meshheading:16242844-Dose-Response Relationship, Drug,
pubmed-meshheading:16242844-Enzyme Inhibitors,
pubmed-meshheading:16242844-Fibroblasts,
pubmed-meshheading:16242844-Fluoroquinolones,
pubmed-meshheading:16242844-Interleukin-6,
pubmed-meshheading:16242844-Leishmania infantum,
pubmed-meshheading:16242844-Leishmaniasis, Visceral,
pubmed-meshheading:16242844-Macrophages,
pubmed-meshheading:16242844-Meglumine,
pubmed-meshheading:16242844-Mice,
pubmed-meshheading:16242844-Nitric Oxide,
pubmed-meshheading:16242844-Organometallic Compounds,
pubmed-meshheading:16242844-Parasitic Sensitivity Tests,
pubmed-meshheading:16242844-Quinolones,
pubmed-meshheading:16242844-Tumor Necrosis Factor-alpha
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate.
|
| pubmed:affiliation |
INSERM U511, Immunobiologie Cellulaire et Moléculaire des Infections Parasitaires, Université Paris VI, CHU-Pitié Salpétrière, 75013 Paris, France. vouldouk@ext.jussieu.fr
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|